StreetInsider.com News Articles

ARS Pharmaceuticals Inc (SPRY) PT Raised to $26 at Leerink Partners

Tue, 10 Mar 2026 06:22:39 -0400

Leerink Partners analyst Roanna Ruiz raised the price target on ARS Pharmaceuticals Inc (NASDAQ: SPRY) to $26.00 (from $25.00) while maintaining a Outperform rating.

The analyst comments "ARS Pharma (SPRY) reported 4Q25 financial results with $20.3M in US net product revenue for neffy ($72.2M for FY25, roughly in line with VA consensus of $73.0M and modestly above our est. of ~$71.8M), reflecting anticipated sequential deceleration from 3Q's $31.3M driven by seasonal 4Q epi market contraction. That said, we think the more important update was the deliberate commercial recalibration that is underway: a) SPRY is expanding its sales force from 106 to

ARS Pharmaceuticals Inc (SPRY) PT Raised to $26 at Leerink Partners

Tue, 10 Mar 2026 06:22:39 -0400

Leerink Partners analyst Roanna Ruiz raised the price target on ARS Pharmaceuticals Inc (NASDAQ: SPRY) to $26.00 (from $25.00) while maintaining a Outperform rating.

Form S-8 ARS Pharmaceuticals,

Mon, 09 Mar 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260309/26131886.html

Form S-8 ARS Pharmaceuticals,

Mon, 09 Mar 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260309/26131886.html

William Blair Reiterates Outperform Rating on ARS Pharmaceuticals Inc (SPRY) following Q4 results

Mon, 09 Mar 2026 08:01:26 -0400

William Blair analyst Tim Lugo reiterated an Outperform rating on ARS Pharmaceuticals Inc (NASDAQ: SPRY)

The analyst commented, "While we acknowledge that ARS faced some headwinds that limited its ability to capitalize on the summer peak to the extent investors wanted, we believe the company is making good progress on its commercial initiatives to drive market share and maximize adoption over the coming quarters. We believe the company has driven meaningful demand for neffy in recent months that should continue to grow and translate into prescriptions and revenue over the coming quarters as several commercial initiatives gain momentum. While the company

Form 10-K ARS Pharmaceuticals, For: Dec 31

Mon, 09 Mar 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260309/26128437.html

Form 10-K ARS Pharmaceuticals, For: Dec 31

Mon, 09 Mar 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260309/26128437.html

Form 8-K ARS Pharmaceuticals, For: Mar 09

Mon, 09 Mar 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260309/26128401.html

Form 8-K ARS Pharmaceuticals, For: Mar 09

Mon, 09 Mar 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260309/26128401.html

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization

Mon, 09 Mar 2026 06:00:00 -0400

neffy delivers $72.2 million of U.S. net product revenue in first full year

Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026

Strong balance sheet of $245.0 million in cash, cash equivalents and short-term investments supports operating plan through anticipated cash-flow break-even

Conference call to be held today, March 9, 2026, at 5:30 a.m. PT / 8:30 a.m. ET

SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization

Mon, 09 Mar 2026 06:00:00 -0400

neffy delivers $72.2 million of U.S. net product revenue in first full year

Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026

Raymond James Reiterates Strong Buy Rating on ARS Pharmaceuticals Inc (SPRY)

Mon, 02 Mar 2026 06:37:03 -0400

Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $34.00 price target on ARS Pharmaceuticals Inc (NASDAQ: SPRY).

The analyst comments "The FDA published a redacted version of the Complete Response Letter (CRL) issued on Feb. 3 to SPRY’s competitor in the needle-free epinephrine space, Aquestive (AQST, Not Covered). In line with what was previously disclosed by Aquestive, the CRL generally does not refer to the wide range of concerns included in SPRY’s Citizen Petition (e.g., diastolic blood pressure spike, dynamic oral environment, repeat-dosing, etc.), but rather focuses on issues that could potentially be resolved with human factors (HF)

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

Mon, 23 Feb 2026 08:00:00 -0400

SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, March 9, 2026 at 5:30 a.m. PT / 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event.

In addition, ARS Pharma Management will be

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

Mon, 23 Feb 2026 08:00:00 -0400

In addition, ARS Pharma Management will be

Form SCHEDULE 13G ARS Pharmaceuticals, Filed by: Rubric Capital Management LP

Fri, 13 Feb 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260213/26000729.html

Form SCHEDULE 13G ARS Pharmaceuticals, Filed by: Rubric Capital Management LP

Fri, 13 Feb 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260213/26000729.html

ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific

Tue, 10 Feb 2026 08:00:00 -0400

-Five poster presentations highlight clinical advancement of neffy, real-world usability and advantages of needle-free epinephrine delivery

-Longer shelf life of nasal epinephrine compared with epinephrine auto-injectors translates into a more affordable, value-based price

-When factoring in patients’ dislike of needle-based administration, the value of a nasal option increased by more than 25%

SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today that five

ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific

Tue, 10 Feb 2026 08:00:00 -0400

-Five poster presentations highlight clinical advancement of neffy, real-world usability and advantages of needle-free epinephrine delivery

-Longer shelf life of nasal epinephrine compared with epinephrine auto-injectors translates into a more affordable, value-based price

-When factoring in patients’ dislike of needle-based administration, the value of a nasal option increased by more than 25%

EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg

Mon, 02 Feb 2026 08:00:00 -0400